# Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

> **NCT06931405** · PHASE2 · RECRUITING · sponsor: **Blueprint Medicines Corporation** · enrollment: 105 (estimated)

## Conditions studied

- Chronic Inducible Urticaria
- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** BLU-808
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06931405
- **Lead sponsor:** Blueprint Medicines Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-28
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06931405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06931405, "Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06931405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*